Mind Medicine (MindMed) I... (MNMD)

AI Score

Unlock

6.43

0.32 (5.24%)

At close: Apr 24, 2025, 3:59 PM

6.43

-0.08%

After-hours: Apr 24, 2025, 07:59 PM EDT

5.24% (1D)

Bid	6.02
Market Cap	471.89M
Revenue (ttm)	n/a
Net Income (ttm)	-108.68M
EPS (ttm)	-1.54
PE Ratio (ttm)	-4.18
Forward PE	-3.49
Analyst	Buy

Ask	6.5
Volume	611,253
Avg. Volume (20D)	1,948,304
Open	6.12
Previous Close	6.11
Day's Range	6.11 - 6.43
52-Week Range	4.70 - 10.44
Beta	2.39

About MNMD

Mind Medicine (MindMed) Inc., a clinical stage biopharmaceutical company, develops novel products to treat brain health disorders related to psychiatry, addiction, pain, and neurology. The company develops MM-120, which is in phase 2 for the treatment of generalized anxiety disorder and attention deficit hyperactivity disorder, as well as for the treatment of chronic pain; and MM-110, an a3ß4 nicotinic cholinergic receptor antagonist that has com...

[Read more]

Industry Biotechnology

Sector Healthcare

IPO Date Nov 15, 2016

Employees 74

Stock Exchange NASDAQ

Ticker Symbol MNMD

Website https://www.mindmed.co

Full Company Profile

Analyst Forecast

According to 9 analyst ratings, the average rating for MNMD stock is "Buy." The 12-month stock price forecast is $20, which is an increase of 210.80% from the latest price.

Stock Forecasts

Why Price Moved

2 months ago

+7.68%

Mind Medicine shares are trading higher after Ever... Unlock content with Pro Subscription

5 months ago

+5.65%

Mind Medicine shares are trading higher. HC Wainwright & Co. reiterated a Buy rating on the stock.

News

18 hours ago · businesswire.com

MindMed to Report First Quarter 2025 Financial Results on May 8, 2025

NEW YORK--(BUSINESS WIRE)--Mind Medicine (MindMed) Inc. (Nasdaq: MNMD), (the "Company" or "MindMed"), a late-stage clinical biopharmaceutical company developing novel product candidates to treat brain...

3 days ago · businesswire.com

MindMed Announces New Employee Inducement Grants

NEW YORK--(BUSINESS WIRE)---- $MNMD--Mind Medicine (MindMed) Inc. (NASDAQ: MNMD) (the “Company” or “MindMed”), a late-stage clinical biopharmaceutical company developing novel product candidates to tr...

1 week ago · businesswire.com

MindMed Announces First Patient Dosed in Phase 3 Emerge Study of MM120 in Major Depressive Disorder (MDD)

NEW YORK--(BUSINESS WIRE)--Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (the "Company" or "MindMed"), a late-stage clinical biopharmaceutical company developing novel product candidates to treat brain...

1 month ago · seekingalpha.com

Mind Medicine (MindMed) Inc. (MNMD) Q4 2024 Earnings Call Transcript

Mind Medicine (MindMed) Inc. (NASDAQ:MNMD ) Q4 2024 Earnings Conference Call March 6, 2025 8:00 AM ET Company Participants Stephanie Fagan - Chief Corporate Affairs Officer Rob Barrow - CEO Dan Karlin...